Jonathan Aschoff
Stock Analyst at Roth MKM
(0.47)
# 3,976
Out of 4,868 analysts
43
Total ratings
23.08%
Success rate
-35.92%
Average return
Main Sectors:
Stocks Rated by Jonathan Aschoff
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| GTBP GT Biopharma | Initiates: Buy | $11 | $2.90 | +279.31% | 1 | Dec 2, 2024 | |
| ZVRA Zevra Therapeutics | Maintains: Buy | $19 → $21 | $9.07 | +131.53% | 2 | Sep 24, 2024 | |
| APVO Aptevo Therapeutics | Maintains: Buy | $11,100 → $5,920 | $5.13 | +115,299.61% | 3 | Sep 23, 2024 | |
| BRTX BioRestorative Therapies | Maintains: Buy | $15 → $18 | $1.70 | +958.82% | 4 | Aug 14, 2024 | |
| NUWE Nuwellis | Reiterates: Buy | $17 | $0.28 | +5,995.37% | 2 | Aug 13, 2024 | |
| OTRK Ontrak | Maintains: Buy | $60 → $45 | $1.39 | +3,137.41% | 2 | Aug 9, 2024 | |
| GOVX GeoVax Labs | Initiates: Buy | $20 | $0.92 | +2,062.86% | 1 | Jul 16, 2024 | |
| CYCC Cyclacel Pharmaceuticals | Maintains: Buy | $336 → $176 | $0.34 | +52,048.15% | 2 | May 3, 2024 | |
| MBRX Moleculin Biotech | Maintains: Buy | $40 | $0.58 | +6,761.06% | 2 | Apr 12, 2024 | |
| CLRB Cellectar Biosciences | Maintains: Buy | $20 → $28 | $0.37 | +7,560.74% | 4 | Mar 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $25 → $36 | $7.09 | +407.76% | 1 | Mar 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $75 → $360 | $0.36 | +99,816.74% | 2 | Mar 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $30 | $5.67 | +429.10% | 3 | Feb 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $200 | $4.37 | +4,476.66% | 1 | Aug 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $14 | $2.37 | +491.97% | 2 | Aug 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $2,400 → $7,200 | $0.79 | +906,016.28% | 2 | Feb 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Buy | $8 | $1.09 | +633.94% | 1 | Jun 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $100 | $2.50 | +3,900.00% | 1 | Feb 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $400 | $0.65 | +61,447.93% | 1 | Nov 24, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $38 | $5.23 | +627.27% | 1 | Mar 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $360,000 | $4.73 | +7,610,893.66% | 1 | Feb 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | $96 | $1.95 | +4,823.08% | 3 | Nov 17, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $13 | $7.24 | +79.56% | 1 | Dec 19, 2019 |
GT Biopharma
Dec 2, 2024
Initiates: Buy
Price Target: $11
Current: $2.90
Upside: +279.31%
Zevra Therapeutics
Sep 24, 2024
Maintains: Buy
Price Target: $19 → $21
Current: $9.07
Upside: +131.53%
Aptevo Therapeutics
Sep 23, 2024
Maintains: Buy
Price Target: $11,100 → $5,920
Current: $5.13
Upside: +115,299.61%
BioRestorative Therapies
Aug 14, 2024
Maintains: Buy
Price Target: $15 → $18
Current: $1.70
Upside: +958.82%
Nuwellis
Aug 13, 2024
Reiterates: Buy
Price Target: $17
Current: $0.28
Upside: +5,995.37%
Ontrak
Aug 9, 2024
Maintains: Buy
Price Target: $60 → $45
Current: $1.39
Upside: +3,137.41%
GeoVax Labs
Jul 16, 2024
Initiates: Buy
Price Target: $20
Current: $0.92
Upside: +2,062.86%
Cyclacel Pharmaceuticals
May 3, 2024
Maintains: Buy
Price Target: $336 → $176
Current: $0.34
Upside: +52,048.15%
Moleculin Biotech
Apr 12, 2024
Maintains: Buy
Price Target: $40
Current: $0.58
Upside: +6,761.06%
Cellectar Biosciences
Mar 28, 2024
Maintains: Buy
Price Target: $20 → $28
Current: $0.37
Upside: +7,560.74%
Mar 7, 2024
Maintains: Buy
Price Target: $25 → $36
Current: $7.09
Upside: +407.76%
Mar 5, 2024
Maintains: Buy
Price Target: $75 → $360
Current: $0.36
Upside: +99,816.74%
Feb 20, 2024
Reiterates: Buy
Price Target: $30
Current: $5.67
Upside: +429.10%
Aug 29, 2023
Reiterates: Buy
Price Target: $200
Current: $4.37
Upside: +4,476.66%
Aug 14, 2023
Reiterates: Buy
Price Target: $14
Current: $2.37
Upside: +491.97%
Feb 14, 2023
Maintains: Buy
Price Target: $2,400 → $7,200
Current: $0.79
Upside: +906,016.28%
Jun 15, 2022
Reinstates: Buy
Price Target: $8
Current: $1.09
Upside: +633.94%
Feb 25, 2022
Initiates: Buy
Price Target: $100
Current: $2.50
Upside: +3,900.00%
Nov 24, 2021
Initiates: Buy
Price Target: $400
Current: $0.65
Upside: +61,447.93%
Mar 11, 2021
Initiates: Buy
Price Target: $38
Current: $5.23
Upside: +627.27%
Feb 12, 2021
Initiates: Buy
Price Target: $360,000
Current: $4.73
Upside: +7,610,893.66%
Nov 17, 2020
Downgrades: Sell
Price Target: $96
Current: $1.95
Upside: +4,823.08%
Dec 19, 2019
Initiates: Buy
Price Target: $13
Current: $7.24
Upside: +79.56%